Unleashing the Power of Big Data in AMD: The Colorado Experience

Naresh Mandava, MD

Sue Anschutz-Rodgers Endowed Chair in Retinal Diseases

Professor and Chair, Ophthalmology

Sue Anschutz-Rodgers Eye Center

Senior Associate Dean for Strategic Advancement

CU Anschutz School of Medicine

Learning Objectives:

At the conclusion of this presentation, participants should be able to understand:

• Describe the best practices for designing a longitudinal multi-omics disease specific registry.
• Explain how systemic immune dysregulation may contribute to the progression of age-related macular degeneration (AMD)
• Describe the value of a multi-omics AMD registry in identifying patients with a higher risk of progression from intermediate AMD to advanced AMD.
• Discuss how artificial intelligence can improve our ability to leverage big data and build algorithmic tools to improve care

Dr. Subramanian reports financial relationship as a consultant for ACELYRIN, Alexion Pharma, Amgen, GenSight Biologics, Invex Therapeutics, Kriya Therapeutics, Neurophth Therapeutics and Viridian Therapeutics, an investigator for Amgen, GenSight Biologics, Immunovant, Invex Therapeutics, Neurophth Therapeutics and Viridian Therapeutics, recipient of a research grant from Amgen and a DSMB member for Argenx. All of the other planners, faculty, or individuals in control of content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this live activity for a maximum of AMA PRA Category 1.5 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.